Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review
Main Article Content
Keywords
Aspirin, Non-steroidal anti-inflammatory drugs, Incidence Mortality
Abstract
Prostate cancer constitutes fifteen percent of all cancers diagnosed in males, it ranks fifth in terms of cancer-related fatalities; and it contributes to 6.6% of all male mortality.
Aim and objectives: To assess the impact of non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin, on the incidence and mortality of prostate cancer.
Patients and methods: This systematic review was performed in April 2021 and chose the related study from PubMed, Web of Science databases, Embase with the following keywords: (“prostate cancer” or “prostate tumor”), (“aspirin” or “acetylsalicylic acid”) ‘anti-inflammatory agents’, ‘NSAID’, and ‘NSAID*.
Results: The current study documented that Regular current aspirin use was found to be correlated with a reduced risk of fatal PC in all participants. The correlation between current post-diagnostic use and increased survival after diagnosis is consistent with the possibility that aspirin inhibits the development of PC. The use of aspirin was not correlated with the incidence of prostate cancer. In contrast, the use of aspirin was inversely correlated with mortality from prostate cancer. Consistent among both white and black men, this association appeared to be limited to men who took aspirin every day or for the prevention of cardiovascular disease. The use of NA-NSAIDs did not correlate with these endpoints.
Conclusion: Potential benefits of aspirin use, as long-term use, include a decreased incidence &mortality rate associated with prostate cancer. Advanced prostate cancer exhibited a significantly increased inverse correlation in comparison to total prostate cancer.
References
2. Gann PH. Risk factors for prostate cancer. Rev Urol. 2002;4(Suppl 5):S3.
3. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 2018;8(12):a030361.
4. Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63.
5. Langley RE, Burdett S, Tierney JF, Cafferty F, Parmar MKB, Venning G. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer. 2011;105(8):1107–13.
6. Liu B, Qu L, Yan S. Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell Int. 2015;15:1–6.
7. Kopp TI, Friis S, Christensen J, Tjønneland A, Vogel U. Polymorphisms in genes related to inflammation, NSAID use, and the risk of prostate cancer among Danish men. Cancer Genet. 2013;206(7–8):266–78.
8. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to cyclooxygenase-2 inhibitors and risk of cancer: nested case–control studies. Br J Cancer. 2011;105(3):452–9.
9. Downer MK, Allard CB, Preston MA, Gaziano JM, Stampfer MJ, Mucci LA, et al. Regular aspirin use and the risk of lethal prostate cancer in the physicians’ health study. Eur Urol. 2017;72(5):821–7.
10. Assayag J, Pollak MN, Azoulay L. The use of aspirin and the risk of mortality in patients with prostate cancer. J Urol. 2015;193(4):1220–5.
11. Flahavan EM, Bennett K, Sharp L, Barron TI. A cohort study investigating aspirin use and survival in men with prostate cancer. Ann Oncol. 2014;25(1):154–9.
12. Grytli HH, Fagerland MW, Fosså SD, Taskén KA. Association between use of β-blockers and prostate cancer–specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol. 2014;65(3):635–41.
13. Jacobs EJ, Newton CC, Stevens VL, Campbell PT, Freedland SJ, Gapstur SM. Daily aspirin use and prostate cancer–specific mortality in a large cohort of men with nonmetastatic prostate cancer. J Clin Oncol. 2014;32(33):3716–22.
14. Veitonmäki T, Murtola TJ, Määttänen L, Taari K, Stenman U, Tammela TLJ, et al. Use of non‐steroidal anti‐inflammatory drugs and prostate cancer survival in the finnish prostate cancer screening trial. Prostate. 2015;75(13):1394–402.
15. Ma Y, Brusselaers N. Maintenance use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk. Prostate Cancer Prostatic Dis. 2018;21(1):147–52.
16. Hurwitz LM, Joshu CE, Barber JR, Prizment AE, Vitolins MZ, Jones MR, et al. Aspirin and non-aspirin NSAID use and prostate cancer incidence, mortality, and case fatality in the atherosclerosis risk in communities study. Cancer Epidemiol Biomarkers Prev. 2019;28(3):563–9.
17. Stark T, Livas L, Kyprianou N. Inflammation in prostate cancer progression and therapeutic targeting. Transl Androl Urol. 2015;4(4):455.
18. Liu Y, Chen JQ, Xie L, Wang J, Li T, He Y, et al. Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis. BMC Med. 2014;12:1–15.
19. Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ. Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. Clin Cancer Res. 2015;21(4):756–62.
20. Zhang Y, Zang T. Association between statin usage and prostate cancer prevention: a refined meta-analysis based on literature from the years 2005-2010. Urol Int. 2013;90(3):259–62.
21. Bansal D, Undela K, D’Cruz S, Schifano F. Statin use and risk of prostate cancer: a meta-analysis of observational studies. 2012;
22. Choe KS, Cowan JE, Chan JM, Carroll PR, D’Amico A V, Liauw SL. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol. 2012;30(28):3540.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.